Introduction {#s1}
============

Recommendations from the Ankylosing Spondylitis Assessment Study (ASAS)/European League Against Rheumatism (EULAR) for the management of ankylosing spondylitis (AS)[@R1] and from EULAR for the management of psoriatic arthritis (PsA)[@R2] are to monitor the disease,[@R1] [@R2] adjust treatment appropriately,[@R2] and adapt the frequency of monitoring depending on the course and severity of the disease.[@R1]

However, no evidence that a guided treatment strategy is as effective for AS and PsA as it is for rheumatoid arthritis (RA)[@R3] has yet been established. This is partly due to the heterogeneity of the presentations of these and related diseases, which some would group under the broader term, spondyloarthritis (SpA). In fact, it has been suggested that the terms axial SpA and peripheral SpA could be considered rather than the traditional names.[@R4] To address this issue, an international panel of expert rheumatologists and patients convened to discuss recommendations on a 'treat-to-target' (T2T) concept for SpA. In line with respective recommendations by EULAR,[@R5] a systematic literature review of the current state of evidence was deemed necessary. In the following, we present this systematic literature review, which served as the background for generating the recommendations document.[@R6]

Methods {#s2}
=======

We performed a systematic literature search of the Medline, Embase and Cochrane databases. This search was based on a PICO (population, intervention, control and outcome) strategy and search terms developed in the course of discussions of the task force\'s steering committee. [Box 1](#bx1){ref-type="boxed-text"} shows the PICO strategy, and online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-203860/-/DC1) S1 lists the search terms. Box 1PICO strategy*Population*: adult patients with axial or peripheral SpA or psoriasis*Intervention*: targeted use of NSAIDs, synthetic DMARDs or biologicals*Control:* routine treatment*Outcome*: the applied definition of a therapeutic target; parameters of disease activity that serve as surrogates for clinical, functional or radiographic success*Design*: 'strategy trial': interventional, prescheduled therapeutic adaptation; RCT, open-label controlled, or single-arm study*Duration*: any given follow-upExcluded: DX: degenerative and dialysis-associated SpA, psoriasis, spondylodiscitisTX: intervention other than drugs (surgery, physiotherapy, balneotherapy, hydrotherapy, exercise, radon, cryotherapy, mud bath), excluded drugs (bisphosphonates, antidepressants, complementary and alternative medicine (CAM)) and excluded applications (intra-articular injections, intravascular steroids)Study setting: non-interventional (ie, observational/retrospective)Publication form: letters, editorials, narrative reviewsCAM, ; DMARD, disease-modifying antirheumatic drug; DX, diagnosis; NSAID, non-steroidal anti-inflammatory drug; RCT, randomised controlled trial; PICO, population, intervention, control, outcome; SpA, spondyloarthritis; TX, treatment.

We retrieved publications from each database\'s inception to September 2011. We also screened 2010 and 2011 EULAR and American College of Rheumatology (ACR) conference abstracts[@R7] [@R8] and accessed the US National Institutes of Health (NIH) database on clinical trials.[@R9] We selected eligible studies according to our inclusion criteria (see [box 1](#bx1){ref-type="boxed-text"} and online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-203860/-/DC1) S1) and compiled the applied measures of disease activity and the thresholds and timelines that guided the decision to change therapy in the respective study protocols. The primary aim of the search was retrieval of strategic studies that compared a therapy steered towards a prespecified treatment target versus a conventional, non-steered approach, as is available for RA.[@R10] Secondly, we reviewed ancillary literature providing circumstantial evidence that a steered therapy might be beneficial during long-term follow-up.

Results {#s3}
=======

We initially retrieved 1976 publications in Medline and Embase, and 1002 in Cochrane. By title and abstract screening, we selected 159 of these for full-text review, and finally included 21 papers plus one additional publication found by hand-search. Of these, 12 trials enrolled patients with AS, five included patients with PsA, and two studies included both AS and PsA patients ([table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"}). No studies on peripheral SpA were obtained; three studies addressed patients with psoriasis. No conference abstracts and no trials from the NIH database provided data on treatment targets. [Figure 1](#ANNRHEUMDIS2013203860F1){ref-type="fig"} illustrates the search and selection process.

###### 

Treatment targets and timeline definition in trials of ankylosing spondylitis and psoriatic arthritis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Measure of disease activity                 Target definition                                                                           Assessment after                         Study (drug)
  ------------------------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------- -----------------------------------
  Ankylosing spondylitis                                                                                                                                                           

   ASAS                                       ≥20% response                                                                               Week 12 (OLE)                            ATLAS (ADA)\*[@R11]

   BASDAI                                     \<3 at both current and prior assessment                                                    Week 36                                  ASSERT (IFX)†[@R12]

   ASAS                                       ≥40% response                                                                               Week 12                                  Haibel (ADA)\*[@R14]

   BASDAI                                     ≥50% reduction, or ≤3                                                                       Week 22 and 38                           CANDLE (IFX)†[@R15]

   BASDAI                                     ≥20% reduction                                                                              Month 3                                  Jois (IFX)[@R17]

                                              ≥50% reduction                                                                              Month 6                                  

   BASDAI                                     ≥40% reduction                                                                              Week 14                                  Cherouvim (IFX)\*[@R18]

   ESR                                        ≥1 mm reduction per week: escalate\                                                         Weekly for escalation\                   Darmawan (IS)†[@R21]
                                              ≤20 (women)/≤10 (men) mm/h for step down\                                                   Month 6 for step down                    
                                              Remission: ESR ≤10 (men ≤5) and\                                                                                                     
                                              BASDAI, BASFI, BASG, BASMI scores mean \<1: taper                                                                                    

  Combined/alternative targets                                                                                                                                                     

   Total back pain (VAS), MST (min)           ≥20% reduction in both back pain and MST                                                    Week 16                                  GO-RAISE (GOL)†[@R13]

   BASDAI, IFX serum level                    \<40 and\                                                                                   After 4th IFX (∼22 weeks)                Meric (IFX)\*[@R16]
                                              5.0 μg/ml                                                                                                                            

   BASDAI, ESR/CRP                            \<4 (BASDAI) or\                                                                            Week 38                                  Collantes (IFX)†[@R19]
                                              \<30 mm/h ESR and \<5 mg/l CRP                                                                                                       

   MST (VAS), pain (VAS), ESR                 ≥20% reduction in 2/3                                                                       Week 4                                   Van Denderen (mesalazine)\*[@R20]

   BASDAI, ESR/CRP                            ≥2 patients. BASDAI reduction and\                                                          Week 2, then 6-weekly                    Cheung (IFX)[@R22]
                                              ≥20% ESR/CRP reduction                                                                                                               

   Q1: disease has remained under control?\   No relapse; definition:\                                                                    ≥4 weeks after stopping for on-demand\   Breban (IFX)†[@R23]
   Q2: disease has been worsening?\           Q1 'Yes' and Q2 'No' and\                                                                   week 40 for dose escalation              
  VAS pain, BASDAI                            either\                                                                                                                              
                                               \<2/10 pain increase and\                                                                                                           
                                               \<1/10 BASDAI increase                                                                                                              

   BASMI, PhysGA                              No relapse; definition:\                                                                    26 weeks after stop                      Braun (IFX)†[@R24]
                                              ≤4 BASMI and\                                                                                                                        
                                              ≤4 PhysGA                                                                                                                            

  Psoriatic arthritis                                                                                                                                                              

   TJC and SJC                                ≥20% reduction                                                                              12 weeks                                 ADEPT (ADA)[@R25]

   TJC and SJC                                ≥10% reduction                                                                              16 weeks                                 GO-REVEAL (GOL)[@R26]

   TJC and SJC combined N                     ≥20% reduction                                                                              38 and 46 weeks                          IMPACT 2 (IFX)[@R27]

   Joint count 'actively inflamed'            ≥30% reduction                                                                              14 weeks                                 Feletar (IFX)[@R28]

   Joint count                                ≥40% reduction                                                                              3 months                                 Rahman (SSZ)[@R29]

   PGA                                        ≥40% reduction                                                                              14 weeks                                 Cherouvim (IFX)[@R18]

   BASDAI, ESR/CRP                            \<4 (BASDAI) or\                                                                            Week 38 (cave diff AB 30/text38)         Collantes (IFX)†[@R19]
                                              \<30 mm/h ESR and \<5 mg/l CRP                                                                                                       

  Psoriasis                                                                                                                                                                        

   MPSS                                       MPSS~present\ visit~ \>MPSS~previous\ visit~−0.2\* (MPSS~previous\ visit~−MPSS~baseline~)   Max 18 weeks                             De Jong (MTX)[@R37]

   PASI                                       Improvement \>25%                                                                           6 weeks                                  Beissert (CsA, MMF)[@R38]

   PASI                                       Improvement ≥75%                                                                            12 weeks                                 Nevin (CsA)[@R39]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Target measure is identical with primary end point measure.

†Target measure is not identical with primary end point measure.

ADA, adalimumab; ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial; ASAS, Ankylosing Spondylitis Assessment Study; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASG, Bath Ankylosing Spondylitis Global Score; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; CsA, ciclosporin; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GOL, golimumab; IFX, infliximab; IS, immunosuppressant therapy (consisting of combined DMARDs); mesa, mesalazine; MMF, mycophenolate mofetil; MPSS, Modified Psoriasis Severity Score; MST, morning stiffness; MTX, methotrexate; OLE, open label extension; PASI, Psoriasis Area Severity Index; PGA, Patient global assessment of disease activity; PhysGA, physician global assessment; Q1, Q2, question 1 and 2; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender joint count; VAS, visual analogue scale.

![Search and selection process. AS, ankylosing spondylitis; clin, clinical; DX, diagnosis; PsA, psoriatic arthritis; publ., publication; T2T, treatment to target; TX, treatment.](annrheumdis-2013-203860f01){#ANNRHEUMDIS2013203860F1}

The most important result of the search was the failure to find any randomised comparison evaluating a T2T approach versus routine treatment. However, several publications report on targets and timelines that were used as thresholds before escalating therapy.

Axial SpA (including AS and non-radiographic axial SpA) {#s3a}
-------------------------------------------------------

Overall, we found 14 studies[@R11; @R12; @R13; @R14; @R15; @R16; @R17; @R18; @R19; @R20; @R21; @R22; @R23; @R24] with predetermined treatment targets in AS that were suitable for inclusion. [Table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"} specifies the measures of disease activity or function and timelines as well as cut-off points used as indication of (in)sufficient response. The baseline characteristics of the study populations were comparable with regard to inclusion criteria, disease activity, function, age and disease duration (online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-203860/-/DC1) S2 lists details of the included studies and baseline characteristics of the patients).

### Definitions of treatment targets and timelines {#s3a1}

The majority of studies used the Bath AS Disease Activity Index (BASDAI) at follow-up for treatment 'escalation' until a prespecified outcome was achieved.[@R12] [@R15] [@R17] [@R18] This outcome was defined as BASDAI\<3 at two consecutive assessments starting from weeks 30 and 36 in one trial,[@R12] while in most studies, a percentage reduction from baseline was required, being either ≥20% after 12 weeks,[@R17] ≥40% after 14 weeks[@R18] or ≥50% after 6 months.[@R15] [@R17] Two protocols required a decline of ≥20%[@R11] or ≥40%[@R14] in the response criteria of the ASAS after 12 weeks. One study[@R21] based treatment decisions on the erythrocyte sedimentation rate (ESR) at follow-up and required a ≥1 mm reduction per week. One trial that included AS and PsA patients[@R18] required a ≥40% reduction in patient global assessment of disease activity (PGA) after 14 weeks, otherwise infliximab (IFX) frequency was increased from an 8-weekly to a 4-weekly schedule ([table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"}).

Several authors used combined targets, mostly combinations of the BASDAI[@R19] [@R22] or the Bath AS Metrology Index (BASMI)[@R24] with either acute phase reactants[@R19] [@R22] or the physician global assessment (PhysGA).[@R24] Meric *et al*[@R16] measured serum IFX levels after four infusions to customise infusion schedules previously determined according to the BASDAI. Reductions in morning stiffness and pain were used to adjust golimumab therapy[@R13] and---expanded by the ESR---also to guide dose escalations of mesalazine.[@R20] Cheung *et al*[@R22] reported therapeutic outcomes using Australian Pharmaceutical Benefit Schedule standards, which only reinforce 'continuation' of IFX after decline of BASDAI by ≥2 points and ≥20% improvement in ESR and/or C-reactive protein (CRP) ([table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"}). Several studies tested the efficacy of 'on-demand' treatment in the case of relapse after cessation of IFX.[@R23] [@R24] The definition of relapse was based on a short questionnaire in combination with BASDAI and an increase in acute phase reactants ([table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"}),[@R23] or an absolute BASMI or PhysGA of ≥4.[@R24] Therapy was tapered according to ESR,[@R21] BASDAI and serum IFX levels[@R16] ([table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"}).

In AS, prospective analyses to identify the predictive value of the above measures for long-term functional and radiographic outcomes have not been carried out.

Psoriatic arthritis {#s3b}
-------------------

Seven studies fulfilled our inclusion criteria for PsA.[@R18] [@R19] [@R25; @R26; @R27; @R28; @R29] [Table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"} details their treatment targets. Online supplementary table S2 shows study details and patients' baseline characteristics.

In the majority, the treatment target was a reduction in swollen and tender joint counts.[@R26; @R27; @R28; @R29] The prespecified decrease for a treatment to be considered sufficiently effective was a reduction in joint counts of ≥10% after 16 weeks,[@R26] ≥20% after 38 and 46 weeks,[@R27] [@R29] ≥30% after 14 weeks[@R28] or ≥40% after 3 months.[@R29] Two trials[@R18] [@R19] included mixed SpA populations and used ≥40% reduction in PGA after 14 weeks[@R18] or ESR and CRP[@R19] ([table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"}). Some prospective studies investigated the correlation between clinical symptoms and progression of radiographic damage and reported a predictive capacity of synovitis,[@R30; @R31; @R32] dactylitis[@R33] and CRP,[@R34] while other authors did not observe these associations.[@R35] Serological markers that can predict long-term outcome in PsA are under investigation.[@R36]

There were no trials available that specifically investigated targeted treatment in other peripheral SpAs or contributed evidence on correlation with long-term outcomes.

Psoriasis {#s3c}
---------

In psoriasis also, there are no randomised controlled trials available to compare T2T with routine treatment. The Modified Psoriasis Severity Score (MPSS) was used to titrate weekly dosage of methotrexate,[@R37] and the Psoriasis Area and Severity Index (PASI) was used to titrate ciclosporin[@R38] [@R39] or mycophenolate mofetil[@R38] ([table 1](#ANNRHEUMDIS2013203860TB1){ref-type="table"} and online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-203860/-/DC1) S2). Other than that, there has been no defined target to guide treatment escalation, although some studies used thresholds to decide whether to pause therapy---for example, to pause etanercept as soon as a target of PGA of ≤2 (clear, almost clear or mild) was reached.[@R40]

Discussion and conclusion {#s4}
=========================

We present a systematic review of targeted treatment for SpA and psoriasis that informed the consensus-finding process of the expert committee for T2T-SpA recommendations.

Randomised trials designed to compare targeted treatment with another type of care are not available, but evidence can be derived from studies that apply target-oriented treatment adaption. The majority of designs suggest use of the BASDAI to evaluate therapeutic response in AS (but other composite measures such as ASDAS[@R41] [@R42] seem to be increasingly used), swollen and tender joint counts for PsA, and MPSS and PASI for psoriasis. In many studies, response was evaluated after 12--14 weeks, while others stretched out to 36 weeks. Importantly, no information on long-term outcomes is available. Composite measures of disease activity have not yet been formally evaluated for PsA. Likewise, no such studies are available for other peripheral spondyloarthritides including reactive arthritis. Some trials for reactive arthritis used antibiotic therapy (reviewed by Hannu[@R43]). These studies are not included here because they did not use criteria for insufficient response.

The definition of pertinent treatment targets for SpA is challenging because of the heterogeneity of the disease, including axial, peripheral and extra-articular/extraspinal manifestations. Moreover, no data on a positive effect on physical function and radiographic damage resulting from a T2T strategy have been published for SpA.

The data presented informed the task force on the current state of evidence and clearly reveal that further research is needed. In particular, clinical trials comparing the value of treatment steered by levels of disease activity versus conventional therapy in SpA, both axial and peripheral, are needed.
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